Companies

Kenvue Inc.

KVUE · CIK 0001944048 · operating

$18.87-1.33%Last updated Mar 2, 5:15 PM

Key Statistics

Valuation

Market Cap$36.16B
P/E24.84
Fwd P/E15.74
PEG
P/S2.39
P/B3.36
EV/EBITDA13.65
EV/Rev2.93

Profitability

Gross Margin58.13%
Op. Margin15.96%
Net Margin9.72%
ROE13.66%
ROA5.43%
FCF Margin11.39%

Financial Health

Current Ratio0.96
Debt/Equity1.52
Free Cash Flow$1.72B
Div. Yield4.34%

Growth & Other

Revenue Growth-2.14%
EPS Growth40.74%
Beta0.55
52W High$25.17
52W Low$14.02

About Kenvue Inc.

Kenvue Inc. operates as a consumer health company offering over-the-counter medications, personal care products, and health-related goods across multiple categories. The company's portfolio spans cough and cold remedies, pain management, digestive health, smoking cessation aids, and eye care products, alongside a comprehensive range of skincare, haircare, and sun protection items. Additionally, Kenvue manufactures oral care, baby care, women's health, and wound care products distributed through retail, pharmacy, and e-commerce channels globally.

The company organizes its business into three primary segments. Self Care encompasses brands such as Tylenol, Motrin, Benadryl, Nicorette, and Zyrtec, addressing common ailments and wellness needs. Skin Health and Beauty includes Neutrogena, Aveeno, Rogaine, and OGX, focused on dermatological and cosmetic applications. Essential Health comprises Listerine, Johnson's, Band-Aid, and Stayfree, serving oral, infant, and personal hygiene categories.

Kenvue maintains a substantial operational footprint with approximately 22,000 full-time employees and operates across North America, Europe, the Middle East, Africa, Asia-Pacific, and Latin America. The company was incorporated in Delaware in 2022 and is headquartered in Summit, New Jersey. Its consumer-focused product portfolio positions it within the household and personal products industry, serving both developed and emerging markets through established brand recognition and distribution networks.

Earnings Per Share (Annual · SEC XBRL)

Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.

Fiscal YearEPS DilutedEPS BasicYoY
2025$0.76$0.77+40.7%
2024$0.54$0.54+217.6%
2023$0.17$0.17

Annual Reports (10-K) · 3 filings

Report DateFiledAccession Number
2025-12-282026-02-200001944048-26-000030SEC ↗
2024-12-292025-02-240001944048-25-000033SEC ↗
2023-12-312024-03-010001944048-24-000057SEC ↗